vironmental stimuli, organisms develop complex cell signaling pathways consisting of receptors, kinase cascades, and other regulatory proteins. Recently, JMCB has published a number of research articles uncovering new members (Perez et al., 2012; RayegoMateos et al., 2013) or regulating mechanisms (Suo et al., 2012; Won et al., 2012; Zhang et al., 2013) of various cell signaling pathways. In this issue, more research works provide new information for understanding the molecular mechanisms and functions of TGF-b signaling as well as other cell signaling pathways for pathological responses.
TGF-b signaling plays important roles in regulating T cell differentiation and the immune responses (reviewed by Tran, 2012) . In the first article of this issue, Dr Gruber and colleagues identified that Cbl-b, a RING-type E3 ligase, directly interacted with SMAD7 and caused its ubiquitination, indicating that Cbl-b might control TGF-b signaling during T cell responses by directly targeting SMAD7 for degradation.
The finding that CD4 + Treg cells could induce TGF-b-dependent infectious tolerance in dendritic cells was reported in last year by Dr Zheng's group (Lan et al., 2012) . In this issue, they collaborating with Dr Han's group showed that in acute liver injury, downregulation of nTreg cells in the acute phase was followed by activation of TGF-b in a matrix metalloproteinase-13-dependent manner and regeneration of induced Treg cells, which contributed to terminating inflammation and allowing for wound healing in the healing phase. These works imply that T cells mediate various pathological responses through the regulation of TGF-b signaling.
It is reported that thromboxane A2 receptor (TP) is aberrant in lung cancer tissues of smokers. In this issue, Dr Chen's group showed that both thromboxane synthase (TxAS) and TP-a were increased in a mouse model of lung tumor induced by a smoke-carcinogen 4-methylnitrosamino-1-3-pyridyl-1-butanone (NNK). They further demonstrated that NNK-induced TP-a upregulated TxAS expression and increased thromboxane A2 (TxA2) synthesis, while the newly synthesized TxA2 further activated TP-a. This study indicates that TxAS and TP-a constitute an auto-positive feedback loop to exaggerate lung tumor growth, suggesting that both of them might be promising drug targets for treating smoking-related lung cancer.
Angiogenesis is critic for tumor growth and metastasis. Dr Pützer's laboratory reported in this issue that the tumor cell-associated vascular endothelial growth factor-C/receptor-3 (VEGF-C/VEGFR-3) signaling was regulated by a transcription factor E2F1. The authors showedthat upregulation of E2F1incancercellsincreased the expression of VEGFR-3 and its ligand VEGF-C, while downregulation of E2F1 suppressed their expression. Furthermore, the authors demonstrated that E2F1 and VEGFR-3 signaling could form a positive feedback loop to stimulate pro-angiogenic plateletderived growth factor B. This work might provide a new anti-angiogenic strategy by inhibiting E2F1 expression.
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